L J A Heitz-Mayfield1, G E Salvi2, A Mombelli3, M Faddy4, N P Lang5. 1. Centre for Rural and Remote Oral Health, The University of Western Australia, Crawley, WA, Australia. 2. School of Dental Medicine, The University of Bern, Bern, Switzerland. 3. School of Dental Medicine, The University of Geneva, Geneva, Switzerland. 4. Queensland University of Technology, Brisbane, Qld, Australia. 5. The University of Hong Kong, Hong Kong, China.
Abstract
AIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment.
AIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment.
Authors: Leonardo Antunes Trindade; Julyana de Araújo Oliveira; Ricardo Dias de Castro; Edeltrudes de Oliveira Lima Journal: Clin Oral Investig Date: 2015-03-26 Impact factor: 3.573
Authors: Manuel Toledano-Osorio; Cristina Vallecillo; Raquel Toledano; Fátima S Aguilera; María T Osorio; Esther Muñoz-Soto; Franklin García-Godoy; Marta Vallecillo-Rivas Journal: Int J Environ Res Public Health Date: 2022-05-26 Impact factor: 4.614